-
在结果中检索

检索结果分析

结果分析中...
检索条件："关键词=death-1 "
共 条 记 录，以下是1-10

发文量、被引量趋势图

全选清除导出
参考文献引证文献引用追踪
视图：
排序：
显示条数：
Immunotherapy prototype Mark 3.0 model in primary liver cancer:adding locoregional stereotactic therapy and prognostic factors classification management被引量：2
《Medical Review》2022年第6期547-552,共6页Xu Yang Nan Zhang Yang Song Xiaobo Yang Xinting Sang Haitao Zhao 
supported by National High Level Hospital Clinical Research Funding[2022-PUMCH-B-128],CAMS Innovation Fund for Medical Sciences(CIFMS)[2022-I2M-C&T-A-003][2021-I2M-1-061][2021-I2M-1-003];CSCO-hengrui Cancer Research Fund[Y-HR2019-0239][Y-HR2020MS-0415][Y-HR2020QN-0414];CSCO-MSD Cancer Research Fund[Y-MSDZD2021-0213]and National Ten-Thousand Talent Program.
Immune checkpoint inhibitors(ICIs)like programmed cell death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitor have shown considerable efficacy in several important cancers including primary liver cancer(PLC)like hepa...
关键词：hepatocellular carcinoma immune checkpoint inhibitors primary liver cancer prognostic factors programmed cell death-1 stereotactic therapy 
检查点抑制剂免疫疗法对罕见皮肤癌有效
《国际生物制品学杂志》2018年第5期224-224,共1页邹力(整理) 樊蓉(校) 
60例晚期结缔组织增生性黑色素瘤患者中，70％对程序性死亡蛋白1（programmed death-1，PD-1）通路阻断剂产生应答，其中19例患者获得5年无复发的完全疗效。生物标记物分析显示，结缔组织增生性黑色素瘤具有高表达水平的PD-1配体及高密...
关键词：免疫疗法 结缔组织增生性 皮肤癌 抑制剂 检查点 CD8^+T细胞 death-1 黑色素瘤 
Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2
《Science China(Life Sciences)》2025年第1期189-203,共15页Wenjie Li Wenyi Mei Hewei Jiang Jie Wang Xiaoli Li Lina Quan Yanyan Diao Yanni Ma Sisi Fan Zhuwei Xie Mengdie Gong Huan Zhu Dewen Bi Feng Zhang Lei Ma Jian Zhang Yufeng Gao Aris Paschalidis Honghuang Lin Fangfang Liu Kangdong Liu Mingliang Ye Zhenjiang Zhao Yajun Duan Zhuo Chen Yufang Xu Weilie Xiao Shengce Tao Lili Zhu Honglin Li 
supported in part by the National Natural Science Foundation of China (81825020, 82150208, 82260682);the National Key R&D Program of China (2022YFC3400501, 2022YFC3400504);the Shanghai Science and Technology Commission Biomedical Science and Technology Support Special Project (21S11907900, 20S11901000);Project of Yunnan Characteristic Plant Screening and R&D Service CXO Platform (2022YKZY001);sponsored by the National Program for Special Supports of Eminent Professionals;National Program for Support of Top-notch Young Professionals
Targeting the PD-1/PD-L1 axis with small-molecular inhibitors is a promising approach for immunotherapy.Here,we identify a natural pentacyclic triterpenoid,Pygenic Acid A(PA),as a PD-1 signaling inhibitor.PA exerts an...
关键词：pygenic acid A programmed death-1 immunoreceptor tyrosine-based switch motif SH2 domain-containing protein-tyrosine phosphatase-2 target identification site recognition 
Effects of Maxingloushi decoction on immune inflammation and programmed death markers in mice with chronic obstructive pulmonary disease被引量：9
《World Journal of Emergency Medicine》2022年第1期40-45,共6页Li Li Jun Yan Lin-qin Ma Wei Bi Cai-jun Wu 
supported by a grant of clinical effi cacy evaluation and mechanism of severe infection intervention based on the theory of“simultaneous treatment of bacteria and toxin”(DZMKJCX-2020-027).
BACKGROUND: To investigate effects of Maxingloushi decoction on lung inflammation and programmed death markers(programmed death-1 [PD-1], programmed death-ligand 1 [PD-L1]) in the lung tissue, peripheral blood, and br...
关键词：Chronic obstructive pulmonary disease Programmed death-1 Programmed death-ligand 1 MICE IMMUNE Maxingloushi decoction 
Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches
《World Journal of Immunology》2015年第1期1-15,共15页Mira A Patel Jennifer E Kim Jacob Ruzevick Michael Lim 
Immune regulation of aggressive tumor growth is often outpaced by tumor up-regulation of ligands that inhibit effector immune responses through the activation of immune checkpoints. A few of such checkpoints include p...
关键词：Programmed death-1 CYTOTOXIC T LYMPHOCYTE associated antigen-4 IPILIMUMAB Nivolumab IMMUNE checkpoint 
Immune checkpoint:The novel target for antitumor therapy被引量：3
《Genes & Diseases》2021年第1期25-37,共13页Xianghu Jiang Guohong Liu Yirong Li Yunbao Pan 
the National Natural Science Foundation of China(81872200,31900558);the Natural Science Foundation of Hubei Province(2018CFB510);the Zhongnan Hospital of Wuhan University Science,Technology and Innovation Seed Fund(CXPY2017029);the Fundamental Research Funds for the Central Universities(2042018kf0091).
Inhibitory checkpoint molecules include programmed cell death-1(PD-1),programmed cell death ligand-1(PD-L1),cytotoxic T lymphocyte antigen-4(CTLA-4),human endogenous retrovirus-H Long terminal repeat-associating 2(HHL...
关键词：Circulating tumor DNA(ctDNA) Cytotoxic Tlymphocyteassociated protein 4(CTLA-4) Exosome Immune checkpoint Lymphocyteactivation gene 3(LAG-3) Programmed cell death protein ligand 1(PD-L1) Programmed death-1 receptor(PD-1) T cell immunoglobulin 
程序性细胞死亡受体-1及其配体在风湿免疫病中的研究进展被引量：1
《中华风湿病学杂志》2018年第1期48-50,共3页张霞 张文 
国家自然科学基金（81373190,81571587,81671620）
程序性细胞死亡受体-1（programmed cell death-1，PD—1）是可诱导表达的免疫调节受体，与其配体结合后可抑制T细胞、B细胞、抗原递呈细胞（antigen presenting cell，APC）的活化，参与免疫耐受的维持。
关键词：风湿免疫病 死亡受体 配体结合 T细胞 程序性 death-1 抗原递呈细胞 cell 
Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma被引量：13
《World Journal of Gastroenterology》2018年第17期1839-1858,共20页Naofumi Mukaida Yasunari Nakamoto 
Supported by(in part)Research Programs on the Innovative Development and Application for New Drugs for Hepatitis B(No.17fk0310116h0001) from the Japan Agency for Medical Research and Development(AMED);Extramural Collaborative Research Grant of Cancer Research Institute,Kanazawa University
Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells(APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor imm...
关键词：NATURAL KILLER T CELL NATURAL KILLER CELL chimeric ANTIGEN RECEPTOR T CELL T CELL RECEPTOR cytokine-induced KILLER CELL program death-1 cytotoxic LYMPHOCYTE antigen-4 regulatory T CELL dendritic CELL myeloid-derived suppressor CELL PD-ligand 1 peptide vaccine tumor-associated ANTIGEN tumor infiltrating LYMPHOCYTE 
PD-1/PD-L1信号通路与肿瘤被引量：6
《解剖科学进展》2017年第5期525-528,共4页杜国强 王瑾 
国家自然科学基金青年基金(81202126)
程序性死亡因子-1(Programmed death-1,PD-1)及配体(Programmed death ligand-1,PD-L1)作为一组免疫检验点共抑制分子通过激活下游信号通路抑制T细胞的活化、增殖及细胞因子的分泌,诱导效应T细胞凋亡。肿瘤发生时,PD-1/PD-L1表达异常增...
关键词：信号通路 肿瘤发生 death-1 T细胞凋亡 共抑制分子 抗肿瘤效应 死亡因子 免疫检验 
Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B被引量：16
《World Journal of Gastroenterology》2014年第28期9486-9496,共11页Cheng-Zhong Li Jing-Jing Hu Jian-Ya Xue Wei Yin Ya-Yun Liu Wen-Han Fan Hao Xu Xue-Song Liang 
Supported by The Shanghai Natural Science Fund,No.09ZR1400500;the National Natural Science Foundation of China,No.30972600;the GuangHui Fund of Hepatitis Prevention Fund Committee China,No.GHZ20100204;the Shanghai Health Bureau Fund,No.2012092
AIM: To determine the relationship between host immunity and the characteristics of viral infection or nucleoside analogues (NAs) themselves in patients with chronic hepatitis B (CHB) receiving NA therapy.
关键词：Chronic hepatitis B Nucleoside analogues Immune modulation Programmed death-1 CD4+CD25+FoxP3+T regulatory cells 
全选清除导出
共8页<12345678>
检索报告 对象比较 聚类工具 使用帮助 返回顶部